Skin and subcutaneous diseases account for 44.84 million DALYs globally in 2021, ranking seventh in disability burden.

Ruxolitinib 1.5% cream significantly reduces pruritus and lesion severity among adults with prurigo nodularis for up to 12 weeks of treatment.

US-based biopharmaceutical company Hoth Therapeutics has reported interim data from a Phase IIa trial of HT-001, a drug ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

Among 200 dialysis patients, 37% were non-compliant with their phosphate binders compared with 12% to 18% of patients who ...

A study from researchers at the Tehran University of Medical Sciences has found that psilocin significantly reduced ...

Series C round led by Deep Track Capital with participation from additional new and existing investorsFinancing will fund early-to-mid-stage ...

Hoth Therapeutics (HOTH) announced positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® (maralixibat) for the treatment of ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.